PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20933540-2	2011	Firstly, amino-remained chitosan-graft-poly (e-caprolactone) (CS-g-PCL) was synthesized with a facile one-step manner by grafting e-caprolactone oligomers onto the hydroxyl groups of CS via ring-opening polymerization by using methanesulfonic acid as solvent and catalyst.	polycaprolactone	45-59	polycystic kidney disease 2-like 1	Mus musculus	67-70	
20047821-2	2010	In particular, cationic chitosan-graft-polycaprolactone (CS-g-PCL) copolymers were synthesized with a facile one-pot manner via ring-opening polymerization of epsilon-CL onto the hydroxyl groups of CS by using methanesulfonic acid as solvent and catalyst.	polycaprolactone	39-55	polycystic kidney disease 2-like 1	Mus musculus	62-65	
21499434-2	2011	In the present study, cationic chitosan-graft-poly(e-caprolactone)/polycaprolactone (CS-PCL/PCL) hybrid scaffolds were successfully prepared by electrospinning.	polycaprolactone	67-83	polycystic kidney disease 2-like 1	Mus musculus	85-95	
29287231-2	2018	Poly(epsilon-caprolactone)/PCL is widely used in medical devices, tissue engineering, and drug delivery systems.	polycaprolactone	0-26	polycystic kidney disease 2-like 1	Mus musculus	27-30	
19736995-1	2009	Biodegradable poly(epsilon-caprolactone)/poly(ethylene glycol) (PCL/PEG) copolymer nanoparticles showed potential application in drug delivery systems.	polycaprolactone	14-40	polycystic kidney disease 2-like 1	Mus musculus	64-67	
19736995-2	2009	In this article, monodisperse poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) (PCL/PEG/PCL, PCEC) nanoparticles, approximately 40 nm, were prepared by solvent extraction method using acetone as the organic solvent.	polycaprolactone	30-56	polycystic kidney disease 2-like 1	Mus musculus	107-110	
19736995-2	2009	In this article, monodisperse poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) (PCL/PEG/PCL, PCEC) nanoparticles, approximately 40 nm, were prepared by solvent extraction method using acetone as the organic solvent.	polycaprolactone	79-105	polycystic kidney disease 2-like 1	Mus musculus	107-110	
34993184-2	2021	We have previously reported the successful regeneration of good-quality cartilage in a nude mouse model using the electrospun gelatin/polycaprolactone (GT/PCL) nanofiber membranes.	polycaprolactone	134-150	polycystic kidney disease 2-like 1	Mus musculus	155-158	
34474864-3	2021	Here, we engineered a BMAT analog made of a GelMA (gelatin methacryloyl) hydrogel/medical-grade polycaprolactone (mPCL) scaffold composite to structurally and biologically mimic key aspects of the bone marrow microenvironment, and exploited an innovative bioreactor to study the effects of mechanical loading.	polycaprolactone	96-112	polycystic kidney disease 2-like 1	Mus musculus	114-118	
33869154-2	2021	Biodegradable medical-grade polycaprolactone (mPCL) scaffolds designed and rooted in evidence-based research offer a promising alternative to overcome the limitations of routinely used silicone implants for breast reconstruction.	polycaprolactone	28-44	polycystic kidney disease 2-like 1	Mus musculus	46-50	
35335450-3	2022	Herein, poly (epsilon-caprolactone) (PCL) and poly (lactic-co-glycolic acid) (PLGA) polymers were used to make scaffolds and were functionalized with peptides (RGD (Arginine-glycine-aspartate), VEGF (Vascular endothelial growth factor), laminin) or gelatin to augment engraftment.	polycaprolactone	8-35	polycystic kidney disease 2-like 1	Mus musculus	37-40	
33307369-1	2021	Biomimetically designed medical-grade polycaprolactone (mPCL) dressings are 3D-printed with pore architecture and anisotropic mechanical characteristics that favor skin wound healing with reduced scarring.	polycaprolactone	38-54	polycystic kidney disease 2-like 1	Mus musculus	56-60	
30325093-3	2018	In this work, the potential of three-dimensional (3D) nanofibrous graphene and poly(caprolactone) (PCL + G) composite scaffold for cardiac tissue engineering has been explored for the first time.	polycaprolactone	79-97	polycystic kidney disease 2-like 1	Mus musculus	99-102	
33039595-2	2020	Thus, we locally applied 3D-printed medical-grade polycaprolactone (mPCL) scaffolds loaded with Doxorubicin (DOX) and measured its effect in a humanized primary bone cancer model.	polycaprolactone	50-66	polycystic kidney disease 2-like 1	Mus musculus	68-72	
30940304-5	2019	In this study, leflunomide-loaded poly(epsilon-caprolactone) implants (leflunomide PCL implants) were evaluated as local drug delivery systems capable of attenuating inflammation and angiogenesis, which represent events of synovitis.	polycaprolactone	34-60	polycystic kidney disease 2-like 1	Mus musculus	83-86	
28374682-3	2017	Melt electrospinning writing allows the design and fabrication of medical grade polycaprolactone (mPCL) fibrous networks for the reinforcement of soft hydrogel matrices for cartilage tissue engineering.	polycaprolactone	80-96	polycystic kidney disease 2-like 1	Mus musculus	98-102	
29909312-4	2018	The traditional Chinese medicine icariin (ICA) was subsequently introduced into poly (epsilon-caprolactone) (PCL) /gelatin nanofibers to fabricate an artificial periosteum for the first time.	polycaprolactone	80-107	polycystic kidney disease 2-like 1	Mus musculus	109-112	
29642582-2	2018	The aim of this study was to develop a new anti-inflammatory scaffold by functionalizing an electrospun nanofibrous poly-epsilon-caprolactone membrane with IBU (IBU-PCL) and to evaluate its impact on periodontal inflammation, wound healing and regeneration in vitro and in vivo.	polycaprolactone	116-141	polycystic kidney disease 2-like 1	Mus musculus	165-168	
28240815-3	2017	In this study, the authors describe the development and characterization of a GBR membrane made of medical grade polycaprolactone (mPCL) electrospun fibers with antibacterial and immunomodulatory properties.	polycaprolactone	113-129	polycystic kidney disease 2-like 1	Mus musculus	131-135	
28032906-2	2017	This study assessed the mineralized tissue forming potential of 3-D printed medical grade polycaprolactone (mPCL) constructs containing osteoblasts (OB) encapsulated in a hyaluronic acid (HA)-hydrogel incorporating bone morphogenetic protein-7 (BMP-7).	polycaprolactone	90-106	polycystic kidney disease 2-like 1	Mus musculus	108-112	
26906227-1	2016	In the study presented here, in order to improve the surface functionality and topography of poly (epsilon-caprolactone) (PCL)/chitosan/PCL hybrid tissue scaffolds fabricated layer by layer with electrospinning technique, an atmospheric pressure nozzle type plasma surface modification was utilized.	polycaprolactone	93-120	polycystic kidney disease 2-like 1	Mus musculus	122-125	
26883261-0	2017	Structural and Surface Compatibility Study of Modified Electrospun Poly(epsilon-caprolactone) (PCL) Composites for Skin Tissue Engineering.	polycaprolactone	67-93	polycystic kidney disease 2-like 1	Mus musculus	95-98	
22965926-1	2013	In this article, the plasma surface modification effects on the chemical, mechanical, and biological properties of electrospun poly (epsilon-caprolactone) (PCL) random nanofiber meshes (NFMs) were investigated by adjusting plasma chemistry, that is, using glow discharges of N(2) +H(2), NH(3) +O(2), and Ar+O(2) gas mixtures.	polycaprolactone	127-154	polycystic kidney disease 2-like 1	Mus musculus	156-159	
23493403-2	2013	In this work, biodegradable micelles made from star-shaped poly(epsilon-caprolactone)/poly(ethylene glycol) (PCL/PEG) copolymer were prepared and used to deliver doxorubicin (Dox) in vitro and in vivo.	polycaprolactone	59-85	polycystic kidney disease 2-like 1	Mus musculus	109-112